| |
|
|
|
|
|
|
|||
|
Blood, 15 December 2005, Vol. 106, No. 13, pp. 4167-4175. Prepublished online as a Blood First Edition Paper on August 30, 2005; DOI 10.1182/blood-2005-04-1723.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Ligand-specific glucocorticoid receptor activation in human plateletsFrom The William Harvey Research Institute, Charterhouse Square, London, United Kingdom.
Few studies have addressed the effects of classical anti-inflammatory glucocorticoids on platelet function. Here, we report for the first time that human platelets contain the glucocorticoid receptor (GR) as identified by a combination of biochemical and functional techniques. Ligand-binding studies revealed the presence of a high- and low-affinity binding site for [3H]-dexamethasone in platelets. The 2 GR ligands prednisolone and dexamethasone competed for [3H]-dexamethasone binding, as did the mineralocorticoid aldosterone. However, while prednisolone (1-10 µM) reduced adenosine diphosphate (ADP, 4 µM) and thromboxane A2 receptor agonist U46619
[GenBank]
induced platelet aggregation (up to 75%), dexamethasone had no effect. The inhibition produced by prednisolone was reversed by preincubation with the GR antagonist mifepristone (10 µM; RU486), suggesting the functional importance of the ligand-receptor complex. In addition, prednisolone caused a marked (
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||